Cardiovascular Risk Following Conversion to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: A Randomized Clinical Trial.

ABSTRACT:

Rationale & objective

In kidney transplant recipients (KTRs), a belatacept-based immunosuppressive regimen is associated with beneficial effects on cardiovascular (CV) risk factors compared with calcineurin inhibitor (CNI)-based regimens. Our objective was to compare the calculated CV risk between belatacept and CNI (predominantly tacrolimus) treatments using a validated model developed for KTRs.

Study design

Prospective, randomized, open-label, parallel-group, investigator-initiated, international multicenter trial.

Setting & participants

KTRs aged 18-80 years with a stable graft function (estimated glomerular filtration rate > 20 mL/min/1.73 m²), 3-60 months after transplantation, treated with tacrolimus or cyclosporine A, were eligible for inclusion.

SUBMITTER: Bredewold OW 

PROVIDER: S-EPMC9803830 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature